French biotech and Pfizer find positives in data for Lyme disease vaccine candidate; Altimmune's obesity drug shows promise in PhI trial
French biotech Valneva and partner Pfizer continued to reveal positive results from its Phase II trial for its Lyme disease vaccine candidate.
The Phase II …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
